research Health‐related quality of life and well‐being in pediatric patients with alopecia areata and their caregivers
Children with alopecia areata and their caregivers experience significant emotional and quality of life challenges.
Search
for
Sort by
Research
240-270 / 1000+ results research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
research Quality of life and willingness-to-pay in patients with androgenetic alopecia
Androgenetic alopecia significantly affects quality of life, especially for women, who are more willing to pay for treatment.
research Alfatradiol (0,025 %) - Eine wirksame und sichere Therapieoption zur Behandlung der androgenetischen Alopezie bei Frauen und Männern
Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
research Low quality of life and high HSS‐29 scores reflect the risk of loss to follow‐up: a study in patients with androgenetic alopecia
Low quality of life and high HSS-29 scores increase risk of losing patients during treatment.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research [Androgenetic alopecia and quality of life].
research Quality of life assessment using dermatology life quality index questionnaire in patients with alopecia attending a tertiary care teaching hospital: A prospective observational study
Most adults with alopecia have some quality of life impairment, mainly minimal to moderate, and are treated with minoxidil.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib is effective for long-term treatment of severe alopecia areata.
research Serum level of Alarin in Patients with Androgenetic Alopecia
Higher Alarin levels may predict androgenetic alopecia and metabolic syndrome.
research Quercetin Nanocrystal Gel: A Novel Topical Therapeutic Strategy for Androgenetic Alopecia
Quercetin nanocrystal gel shows promise for hair regrowth in androgenetic alopecia.
research Comparison of quality of life in patients with androgenetic alopecia and alopecia areata
Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.
research Quality of Life in Alopecia Areata: A Study of 60 Cases
Alopecia areata seriously lowers quality of life, especially affecting self-image, mental health, and social life.
research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
research The Impact of Androgenic Alopecia on the Quality of Life of Male Individuals: A Cross-Sectional Study
Hair loss significantly lowers life quality, especially in young men, with most patients unhappy with treatment effectiveness.
research Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
research ALA-PDT in the Treatment of Diseases of Hair Follicles and Sebaceous Glands
research A liquid chromatography/tandem mass spectrometry method for determination of aristolochic acid‐I in rat plasma
A reliable method was developed to measure aristolochic acid-I in rat blood.
research Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecial Totalis and Alopecia Universalis: A Randomized, Double-Blind, Placebo-Controlled Trial
Botulinum toxin type A did not help regrow hair in severe alopecia cases.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial
ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
research Alopecia linked to quetiapine
Quetiapine may cause hair loss.
research Alopecia associated with quetiapine
Quetiapine may cause hair loss, a side effect not widely recognized before.
research Abstracts Pt.21
research The Dermatology Life Quality Index (DLQI ) used as the benchmark in validation of 101 quality‐of‐life instruments: A systematic review
The DLQI is a key tool for measuring quality of life in dermatology.
research Plasma Rich Platelets Protocol for Androgenetic Alopecia: Development, Implementation and Evaluation: A Quality Improvement Project
The project developed and tested a method using plasma rich platelets to treat hair loss.